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Background: Sporozoite immunization of animals and humans under a chemo-prophylactic cover of chloroquine
(CPS-CQ) efficiently induces sterile protection against malaria. In humans, CPS-CQ is strikingly more efficient than
immunization with radiation attenuated sporozoites (RAS), raising the hypothesis that this might be partially due
to CQ. Chloroquine, an established anti-malarial drug, is also well known for its immune modulating properties
including improvement of cross-presentation. The aim of this study was to investigate whether co-administration of CQ
during sporozoite immunization improves cellular responses and protective efficacy in Plasmodium berghei models.
Methods: A number of experiments in selected complimentary P. berghei murine models in Balb/cByJ and C57BL/6j
mice was performed. First, the effect of CQ administration on the induction of protection and immune responses by RAS
immunization was studied. Next, the effect of CQ on the induction of circumsporozoite (CS) protein-specific CD8+ T cells
by immunization with P. berghei parasites expressing a mutant CS protein was investigated. Finally, a direct comparison
of CPS-CQ to CPS with mefloquine (MQ), an anti-malarial with little known immune modulating effects, was performed.
Results: When CQ was co-administered during immunization with graded numbers of RAS, this did not lead to an
increase in frequencies of total memory CD8+ T cells or CS protein-specific CD8+ T cells. Also parasite-specific cytokine
production and protection remained unaltered. Replacement of CQ by MQ for CPS immunization resulted in significantly
reduced percentages of IFNγ producing memory T cells in the liver (p = 0.01), but similar protection.
Conclusions: This study does not provide evidence for a direct beneficial effect of CQ on the induction of
sporozoite-induced immune responses and protection in P. berghei malaria models. Alternatively, the higher
efficiency of CPS compared to RAS might be explained by an indirect effect of CQ through limiting blood-stage
exposure after immunization or to increased antigen exposure and, therefore, improved breadth of the immune
response.
Keywords: Chloroquine, Sporozoite immunization, P. berghei, T cells, Immunity, ProtectionBackground
Whole sporozoite immunization approaches, such as
chloroquine chemoprophylaxis and sporozoites (CPS-
CQ) and radiation-attenuated sporozoites (RAS), effi-
ciently induce protection in murine malaria models
[1-3]. In humans CPS-CQ is about 20 times more* Correspondence: robert.sauerwein@radboudumc.nl
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unless otherwise stated.efficient than RAS, requiring bites from a total of 45 ver-
sus 1,000 mosquitoes, respectively [4-6]. Moreover, long-
lasting immune responses after CPS-CQ immunization
in studies with mice [7] and healthy human volunteers
[8] go together with protracted protection. Several murine
studies have demonstrated the essential role of CD8+ T cells
in sporozoite-induced pre-erythrocytic immunity [9-14,2].
Generation of these CD8+ T cells against pre-erythrocytic
antigens requires cross-priming by dendritic cells [15].
CQ has since its discovery in 1934 been used widely and
successfully as anti-malarial, until resistance developed [16],his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and viral infections [17,18]. Interestingly, CQ was also
shown to enhance cross-presentation of soluble antigens
and non-replicating influenza virus in vitro [19,20]. More-
over, in vivo cross-priming of naïve CD8+ T cells with
soluble ovalbumin was more effective in CQ–treated com-
pared to untreated mice [21], and CQ improved the induc-
tion of influenza-specific cytolytic T cells in mice [20]. In
humans, co-administration of CQ with a hepatitis B vaccine
booster significantly increased the number of virus-specific
IFNγ-producing CD8+ T cells [19].
This study was based on the hypothesis that CQ,
which affects endosomal acidification and the degrad-
ation and transport of antigens to the cytosol [22,23],
could favour cross-presentation of pre-erythrocytic Plas-
modium antigens and thereby contribute to the efficient
induction of immune responses and protection by
CPS-CQ immunization. The first topic of investigation
was the effect of CQ on immunization by RAS, an
established immunization model relying on CD8+ T
cell responses, thus potentially benefiting from im-
proved cross-presentation. CD8+ T cells recognizing
the immunodominant circumsporozoite (CS) protein
can mediate protective immunity [24]. Therefore, the
effect of CQ on the induction of CS-specific CD8+ T
cells by immunization with P. berghei parasites that
express a mutant CS protein containing the model
SIINFEKL H-2Kb epitope was investigated next. Finally, a
direct comparison was performed betweeen CPS-CQ and
CPS with mefloquine (MQ), an anti-malarial with little
known immune modulating effects [25-27], not including
improvement of cross-presentation. Akin to CQ, MQ in-
duces arrest of early blood-stage parasites without an effect
on pre-erythrocytic parasite stages, allowing full liver-stage
development and brief exposure to early blood stages. By
performing experiments in these selected complimentary
P. berghei murine models, the aim of this study was to ex-
plore the effect of CQ on protection and T cell responses
after whole sporozoite immunization.
Methods
Mice and parasites
Balb/cByJ and C57BL/6j mice (6 to 8 weeks old) were
purchased from Elevage-Janvier (Le Genest Saint Isle,
France). These mouse strains were selected based on
extensive experience with these strains for malaria
immunization studies [28]. The following parasites were
used: P. berghei (ANKA strain) wild type parasites and
P. berghei CS5M parasites in which the endogenous CS
gene had been replaced with a modified circumsporo-
zoite gene expressing the H-2Kb restricted SIINFEKL
[15]. Sporozoites were obtained by dissection of the sal-
ivary glands of infected female Anopheles stephensi mos-
quitoes 21–29 days after a blood meal on infected mice.All animal studies and procedures performed in the
Netherlands were approved by the Ethical Committee
on Animal Research of the Radboud University Nij-
megen (RU-DEC 2009–179, 2009–225, 2010–115,
2010–135). Mice were housed at the Central Animal
Facility in Nijmegen and received a standard diet and
water ad libitum. All animal procedures in the United
States of America were approved by the Institutional
Animal Care and Use Committee of the Johns Hop-
kins University (Protocol Number MO10H167) and
followed the National Institutes of Health guidelines for
animal housing and care.Immunization schedules, sporozoite challenge and
assessment of protection
Mice were immunized with one (Balb/cByJ; Additional
file 1A) or two to three (C57BL/6j; Additional file 1B)
intravenous (iv) injections of P. berghei RAS (16krad,
Gammacel 1000 137Cs) at weekly intervals or with
one intradermal injection of P. berghei CS5M RAS
(Additional file 1: Figure S1C). Dose de-escalation of
RAS immunization was performed in order to obtain a
suboptimal RAS dose to detect possible beneficial ef-
fects of CQ (Additional files 1A and 1B). In RAS exper-
iments, RAS-CQ groups received either CQ prophylaxis
(chloroquine diphosphate, Sigma-Aldrich) for 10 days
(Balb/cByJ –1040 μg base/day oral) or 17 days (C57BL/6j –
800 μg base/day intraperitoneal). Efficacy of these prophy-
lactic regimens was established in pilot studies, and
they were chosen because of their closest resemblance
to the human CPS-protocol. Alternatively, mice
were given two subcutaneous injections of 500 μg CQ
base, 2 h before and 6 h after each immunization,
because this particular regimen was previously shown
to improve cross-presentation (Additional file 1B)
[21,20].
Furthermore, mice under CQ or MQ prophylaxis were
immunized three times at weekly intervals by intraven-
ous administration of 20,000 wild-type PbSPZ (CPS
immunization; Additional file 1D). For CPS immunization,
CQ (diluted in PBS) and MQ (diluted in DMSO/water for
injection) were given orally for 24 consecutive days at dos-
age 1040 μg base/day (CQ) or 350 μg base/day (mefloquine
hydrochloride, Sigma-Aldrich) starting from the first day of
PbSPZ administration.
Challenge infections were performed by intravenous
injection of 10,000 or 50,000 sporozoites around four
or eleven weeks after the end of CQ/MQ prophylaxis.
Giemsa-stained blood smears were screened for para-
sitized red blood cells every other day from days 3–14
and finally on day 21 after challenge. Protection was
defined as the absence of blood-stage parasites until
day 21 post-challenge (Additional files 1A, B and C).
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against sporozoites and blood-stage parasites
Mice were euthanized by isoflurane inhalation after intra-
venous injection of 50 units heparin. Spleen and liver were
collected after perfusion of the liver with 10 ml PBS. Cell
suspensions of liver and spleen were made by passage of
the organs through a 70-μm nylon cell strainer (BD
Labware). Liver cells were re-suspended in 35% Percoll (GE
Healthcare) and centrifuged at 800 g for 20 min. Liver and
spleen erythrocytes were lysed using 5 min incubation on
ice in a lysing solution of ammonium chloride. After
erythrocyte lysis, hepatic mononuclear cells (HMC) and
splenocytes were re-suspended in RPMI 1640 medium.
Five-colour staining of HMC and splenocytes was
performed using monoclonal antibodies purchased from
Biolegend: Pacific blue-conjugated anti CD3 (17A2),
Peridinin Chlorophyll Protein (PerCP)-conjugated anti
CD4 (RM4.5), Alexa fluor 700-conjugated anti CD8a
(53–6.7), fluorescein isothiocyanate (FITC)–conjugated
anti-CD44, allophycocyanin (APC)– or phycoerythrin-
Cy7 (PE-Cy7)-conjugated anti-CD62L (MEL-14). Briefly,
106 cells were re-suspended in cold assay buffer (PBS
supplemented with 0.5% bovine serum albumin (Sigma-
Aldrich)) and incubated for 30 min at 4°C with the
monoclonal antibodies. Cells were fixed with Fix & Perm
medium A (Invitrogen) and collected in an assay buffer
for measurement.
For the detection of parasite-specific cytokine produc-
tion, HMC and splenocytes (5x105 cells/well) were co-
cultured in complete RPMI 1640 culture medium [29] in
the presence of P. berghei cryopreserved sporozoites
(PbSPZ - 5×104/ml) or infected red blood cells (PbiRBC -
5×106/ml). Exposure to salivary gland preparations from
uninfected mosquitoes and uninfected red blood cells
(uRBC - 5×106/ml) were used as respective negative con-
trols. Cells were stimulated at 37°C/5%CO2 for 24 hours
and Brefeldin A (Sigma-Aldrich) was added during the last
four hours (10 μg/ml final concentration). As positive
control, PMA (100 ng/ml) and Ionomycin (1.25 μg/ml)
(Sigma-Aldrich) were added simultaneously along with
Brefeldin A. Cells were harvested after 24-hours in vitro
stimulation and stained with monoclonal antibodies against
CD3, CD4, CD8a and CD44 as indicated above. Fixed and
permeabilized cells were stained with PE-conjugated anti-
IL-2 (JES6-5H4) and APC-conjugated anti-IFNγ (XMG1.2)
in Fix & Perm medium B (Invitrogen) at 4°C for 30 min.
Flow cytometry was performed on a 9-color Cyan ADP
(Beckman Coulter) and data analysis was performed using
FlowJo software (version 9.1; Tree Star), using a gating
strategy as described previously [7].
Quantification of SIINFEKL specific CD8+ T cells
Prior to intradermal immunization with 20.000 P. ber-
ghei CS5M RAS, C57BL/6j mice received 2*103 CD45.1 +OT-1 cells and the RAS-CQ group received a 10-days
CQ treatment (1040 μg base/day – oral). Expansion of
CD45.1+CD8+ SIINFEKL cells in liver and spleen was
assessed by flow cytometry ten days after immunization
as described previously [15] (Additional file 1C).Data analysis and statistics
Difference in protection between two groups was tested
with a Fisher’s exact test. Overall comparisons between
immunized and naïve groups were performed using the
Kruskal-Wallis test. Direct comparisons between two
groups (RAS versus RAS-CQ or CPS-CQ versus CPS-
MQ) were performed by Mann–Whitney U test. For the
analysis of cytokine production, background responses
to salivary glands and uRBC were subtracted from
PbSPZ and PbiRBC responses, respectively, for each in-
dividual mouse. All statistical analyses were performed
using PRISM software version 5.0 (Graphpad, San Diego,
CA). A p-value of ≤0.05 was considered statistically
significant.Results
Effects of chloroquine on RAS immunization
First, experiments were performed to investigate
whether administration of a prophylactic regimen of CQ
improved CD8+ memory T cell responses induced by
RAS immunization in C57BL/6j mice. Ex vivo analysis
showed that percentages of CD8+ T cells with an effector
memory phenotype (CD44+CD62L−; Tem) in the liver
were 4–5 fold higher a day before challenge (C-1) in im-
munized compared to naïve mice (p = 0.011). However,
the percentage of CD8+ Tem cells was similar in RAS
versus RAS-CQ mice (Figure 1A). Similar patterns were
observed in the spleen with three-fold increased Tem
levels at C-1 (p = 0.007, Figure 1B).
In vitro re-exposure of immune cells to PbSPZ showed
high levels of IFNγ producing memory T cells in both
liver and spleen of RAS-immunized mice (p = 0.003 and
0.027, respectively), which were not increased by add-
itional CQ administration (Figure 2A). Similar observa-
tions were made for hepatic and splenic pluripotent
memory T cells producing both IFNγ and IL-2, with a
major contribution of CD8+ cells in the liver (Figure 2B).
In summary, additional CQ administration affected nei-
ther frequency of RAS-induced CD8+ Tem cells, nor
sporozoite-specific cytokine production by T cells.
The circumsporozoite (CS) protein is an established
target protein of protective immunity in mice and
humans [24,30], and the effect of CQ on CD8+ T cell re-
sponses against a SIINFEKL H-2Kb restricted epitope in-
tegrated in this protein was studied next. In line with
the results above, mice immunized with RAS whilst
under CQ cover showed similar percentages of hepatic
Figure 1 Frequencies of CD8+ Tem cells following RAS immunization of C57BL/6j mice under CQ cover. Percentages of CD8+ T cells with
effector memory phenotype (CD44+CD62L− Tem) were measured one day before challenge by direct ex vivo staining in the liver (A) and spleen
(B) of RAS immunized mice (filled squares), RAS immunized and CQ treated mice (open squares), naïve mice (filled circles) and naïve-CQ mice
(open circles). Horizontal lines represent group medians. NS = not significant.
Figure 2 Sporozoite specific cytokine responses following RAS immunization under CQ cover. Percentages of IFNγ (A) and IFNγ and IL-2
(B) producing memory T cells were measured in RAS (n = 5) RAS-CQ (n = 4), naïve control (n = 5) and CQ-control (n = 4) mice, a day before
challenge by intracellular staining after in vitro re-exposure of liver and spleen cells to P. berghei sporozoites (PbSPZ). Responses of CD4+ T cells
(open area), CD8+ T cells (grey area) and CD4−CD8− T cells (dotted area) relative to total memory T cell responses are presented. Background
responses to salivary glands were subtracted from PbSPZ responses for each individual mouse. Error bars represent standard error of the mean.
NS = not significant.
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treated mice (Figure 3).
To evaluate a potential effect of CQ on RAS protective
efficacy, groups of Balb/cByJ and C57BL/6j mice were
immunized with graded numbers of RAS, then chal-
lenged and monitored for parasitemia. In both mice
strains, reduction of immunization dose resulted in a
stepwise decrease in protection that was not influenced
by either a prophylactic regimen of daily CQ, or two
low doses of CQ at 2 h before and 6 h after each
immunization (Table 1).
The CQ administered during immunization had no
effect on the challenge infection, since all control mice
that received CQ-prophylaxis showed the same pre-
patent period as untreated naïve mice.
Comparing chloroquine to mefloquine prophylaxis for
CPS immunization
Next, immune responses and protection after CPS-CQ
and CPS-MQ immunization were investigated. CD8+
Tem levels (Figure 4), IFNγ production upon in vitro
restimulation with PbSPZ or PbiRBC and pluripotent
T cells producing both IFNγ and IL-2 (Figure 5) were
significantly increased in immunized compared to con-
trol mice.
Although not significant, there was a trend for higher
CD8+ Tem levels in CPS-CQ compared to CPS-MQ in
both liver and spleen (p = 0.08 and 0.16, respectively;
Figure 4). T cells isolated from the liver of CPS-CQ mice
showed higher IFNγ responses after in vitro re-exposure
to PbiRBC (p = 0.01) and a trend for higher IFNγ re-
sponses to PbSPZ re-exposure (p = 0.09; Figure 5A). In
the spleen, a similar trend of higher IFNγ responses inFigure 3 Frequencies SIINFEKL specific CD8+ T cells following RAS im
with (RAS-CQ) or without chloroquine (RAS), mice received injection of SIIN
expansion of CD45.1+CD8+ SIINFEKL-specific cells was determined in the livthe CPS-CQ group was observed upon re-exposure to
PbSPZ but not PbiRBC (Figure 5B). Following in vitro
re-exposure to PbiRBC, but not PbSPZ, the percentage of
hepatic pluripotent memory T cells producing both IFNγ
and IL-2 was significantly higher in the CPS-CQ group
compared to the CPS-MQ group (p = 0.02, Figure 5C).
Thus, CPS-CQ resulted in somewhat higher specific cyto-
kine responses compared to CPS-MQ.
Finally, mice were challenged by intravenous adminis-
tration of 10,000 sporozoites five or ten weeks after the
second booster (day 50 or 100) or with 50,000 sporozo-
ites at day 50. At day 50, 100% of CPS-CQ (13/13) and
CPS-MQ (21/21) immunized mice were protected
against challenge with low (10 K) or high (50 K) sporo-
zoite dose. All control mice including CQ (10/10) and
MQ (10/10) prophylaxis groups developed blood-stage
parasitaemia. Postponement of challenge to day 100 re-
sulted in 90% protection (9/10) in both the CPS-CQ and
CPS-MQ group (Table 2).
Altogether, there was no difference in protection after
CPS immunization with either CPS-CQ or CPS-MQ,
although cellular responses after whole sporozoite
immunization under CQ cover were increased.
Discussion
Addition of CQ to a P. berghei RAS immunization
protocol improves neither protection nor parasite-
specific CD8+ T cells responses. Only slightly reduced T
cell responses and similar protective efficacy are found
when CPS-CQ is compared to CPS-MQ. This study did
not involve an investigation of the effect of CQ on
cross-presentation in vitro, nor detailed mechanistic
antigen presentation studies [31]. Alternatively, moremunization under CQ cover. Prior to RAS intradermal immunization
FEKL-specific CD8+ T cells. Ten days after a single immunization,
er and spleen of both immunized groups. NS= not significant.
Table 1 Effect of chloroquine on RAS protective efficacy
No. protected/ no. challenged
Immunization Mouse strain Immunization dose (x103 RAS PbSPZ) Inoculations (n) Chloroquine - Chloroquine +#
RAS Balb/cByJ 1 1 14/16 (88) 13/16 (81)
0.5 1 4/10 (40) 4/10 (40)
0.3 1 5/10 (50) 2/10 (20)
C57BL/6j 10 3 5/5 (100) 4/5 (80)
4 3 4/5 (80) 4/5 (80)
1 3 0/5 (0) 1/5 (20)
4 2 15/23 (65) 14/23 (61)##
None Balb/cByJ N/A N/A 1/6 (16) 0/6 (0)
C57BL/6j N/A N/A 0/10 (0) 0/15 (0)
#Mice received chloroquine prophylaxis for 10 or 17 days, with the exception of the experiment indicated with ##, where mice received two injections of CQ, 2 h
before and 6 h after each immunization.
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specific CD8+ T cell responses and protection from chal-
lenge infection to assess potential immune enhancing ef-
fects of CQ. These combined P. berghei data do not
provide evidence for significant improvement of whole
sporozoite immunization in the presence of CQ and,
therefore, indicate that CQ is not responsible for the
strikingly higher efficiency of CPS-CQ compared to RAS
in humans.
Improved cross-presentation resulting in increased
IFNγ production by CD8+ T cells has been shown in
in vitro studies where dendritic cells were pulsed with
soluble viral antigen in the presence of CQ [19]. In mice,
CQ was shown to enhance cross-presentation of soluble
OVA to OT-I cells both in vitro and in vivo and to im-
prove specific CD8+ T cell responses after alum-OVA
immunization [21]. An effect of CQ on OVA cross-Figure 4 Frequencies of CD8+ Tem cells following sporozoite immuni
effector memory phenotype (CD44+CD62L− Tem) were measured by direct
of C57BL/6j mice immunized with sporozoites under CQ cover (filled triang
naïve-MQ mice (open diamonds) and untreated naïve mice (filled circles). Hpresentation was observed upon administration of 20 μg,
but not 200 μg protein [21], suggesting that immuno-
modulatory effects of CQ are only beneficial under sub-
optimal immunization conditions. In the current study,
RAS immunization both with and without CQ induces
strong cellular responses with similar contribution of
CD8+ T cells, which translates to equal protection levels.
Even after down-titration of RAS immunization dose,
which is associated with decreasing protection, clear im-
provement by CQ remains undetected.
In humans, a single administration of CQ during
Hepatitis B booster vaccination significantly improved
CD8+ T cell response [19]. Despite several reports of en-
hanced immune responses by CQ in mice and men
[21,23,32,19], only one study has reported improved
protection; mice immunized with a heat-inactivated
influenza virus showed improved survival rates afterzation under CQ or MQ cover. Percentages of CD8+ T cells with
ex vivo staining a day before challenge (C-1) in the liver and spleen
le) or MQ cover (filled diamonds), naïve-CQ mice (open triangles),
orizontal lines represent group medians.
Figure 5 Sporozoite specific cytokine responses following sporozoite immunization under CQ or MQ cover. Percentages of IFNγ
producing memory T cells were measured in CPS-CQ (n = 10), CPS-MQ (n-9), naïve-CQ (n = 10), naïve-MQ (n = 10) and no-drug naïve controls
(n = 10) a day before challenge by intracellular staining after re-exposure of (A) liver and (B) spleen cells to P. berghei sporozoites (PbSPZ) or
infected red blood cells (PbiRBC). Responses of CD4+ T cells (open area), CD8+ T cells (grey area) and CD4−CD8− T cells (dotted area) relative to total
memory CD3+ T cell responses are presented. (C) Hepatic IFNγ and IL-2 responses of memory T cells after re-exposure to PbSPZ and PbiRBC are presented
similarly. Background responses to salivary glands and uninfected red blood cells were subtracted from PbSPZ and PbiRBC responses respectively for each
individual mouse. Error bars represent standard error of the mean. NS = not significant.
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immune responses for protection thus remains to be fur-
ther explored.
One cannot assume that improvement of cross-
presentation by CQ is applicable to any soluble pro-
tein or peptide, or antigens presented in the form of a
whole sporozoite. Improvement of cross-presentationof SIINFEKL peptide (OVA257–264) and inactivated influ-
enza virus by CQ in mice have been demonstrated [21,20].
Here however, CQ administration during sporozoite
immunization with SIINFEKL expressing P. berghei sporo-
zoites showed no increase of SIINFEKL-specific CD8+ T
cells, suggesting that presentation pathways and effects of
CQ might differ between pathogens or antigens.
Table 2 Protection by sporozoite immunization under CQ or MQ cover
No. protected/No. challenged (% protection)
Day 50 (x103 PbSPZ challenge) Day 100 (x103 PbSPZ challenge)
10 50 10
CPS-CQ 3/3 (100) 10/10 (100) 9/10 (90)
CPS-MQ 11/11 (100) 10/10 (100) 9/10 (90)
Naïve-CQ 0/5 (0) 0/5 (0) -
Naïve-MQ 0/5 (0) 0/5 (0) -
Naïve 0/5 (0) 0/5 (0) 0/5 (0)
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relatively high and lengthy drug prophylaxis to prevent
development of P. berghei infection (K. Nganou-
Makamdop, unpublished data). As a result, CPS-CQ
mice cumulatively receive much more CQ than the
two doses of 800 μg chloroquine diphosphate salt that
were previously shown to improve cross-presentation
[21]. Therefore, the effect of this low CQ-dose regi-
men on RAS immunization was assessed in a separate
experiment, but protection levels were not higher than
compared to RAS alone, indicating that the choice of
CQ dose was not crucial.
Immune modulating effects of MQ have been reported
but do not include cross-presentation [33,25-27].
It cannot be formally excluded that MQ in CPS
immunization regimes may have similar properties as
CQ. Both CQ and MQ are lysosomotropic agents that
limit endosomal acidification [22], which for CQ is
known to result in inhibition of lysosomal enzymes that
require an acidic pH to function and the fusion of endo-
somes with lysosomes [34]. As such CQ, but not MQ,
has been widely used to study the role of endosomal
acidification in cellular processes [35]. CQ has also been
studied extensively for its inhibitory effect on autophagy
[17], but a recent publication suggests that MQ has
similar effects on autophagy [36]. Because both endo-
somal acidification and autophagy might influence
antigen presentation, the effect of MQ on these pro-
cesses may result in immune modulating effects just as
is the case for CQ.
In the absence of evidence for a direct immune-
modulating effect of CQ during whole sporozoite
immunization, it cannot be ruled out that both CQ and
MQ might instead contribute to the efficient induction
of protection in an indirect way. A review of rodent
sporozoite immunization studies demonstrates the im-
portance of optimal exposure to the entire repertoire of
liver stage antigens as occurs during CPS-CQ and CPS-
MQ, with reduced protective efficacy if liver stage devel-
opment is halted by drugs or in the case of RAS or
genetically attenuated parasites [37]. Furthermore, somereports show a negative effect of blood-stage parasites
on induced pre-erythrocytic CD8+ T cell responses by
interfering with dendritic cell function [38,1]. By limiting
exposure to blood stages during CPS immunization, CQ
and MQ might thus have an indirect positive effect on
pre-erythrocytic immunity.
Conclusions
This study does not provide evidence of improved im-
mune responses or protective efficacy by CQ in the P.
berghei model. Instead, the higher efficiency of CPS
compared to RAS in humans might be explained by an
indirect effect of CQ through limiting blood-stage ex-
posure after immunization or to an improved breadth of
the immune response as a result of increased antigen ex-
posure. In the absence of a clear immune enhancing ef-
fect of CQ here, more work is needed to assess whether
these findings can be translated to human settings.
Additional file
Additional file 1: Study designs. The effect of chloroquine (CQ) on
immune responses and protection by whole sporozoite immunization
was tested in a number of P. berghei models. Balb/cByJ (A) and
C57BL/6j mice (B) received intravenous (iv) immunizations with radiation
attenuated sporozoites (RAS; immunization dose in grey), with or without
additional administration of CQ (grey bars). All mice were challenged
by iv injection of 10x103 wild type (WT) P. berghei sporozoites (spz), and
followed up with blood smears for the detection of parasites. (C) C57BL/
6j mice were immunized with P. berghei CS5M RAS after receiving CD45.1
+ OT-1 cells, with or without CQ prophylaxis (grey bar). Expansion of
CD45.1+CD8+ SIINFEKL cells in liver and spleen was assessed by flow
cytometry 10 days after immunization. (D) C57BL/6j mice were
immunized by iv administration of WT P. berghei spz while receiving
either CQ or mefloquine (MQ) prophylaxis, then challenged after 50
days with either 10x103 or 50x103 WT berghei spz or after 100 days with
10x103 WT berghei spz, and followed up with blood smears for the
detection of parasites.
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CQ: Chloroquine; CPS: Chemoprophylaxis and Sporozoites; CS
protein: Circumsporozoite protein; HMC: Hepatic mononuclear cell;
MQ: Mefloquine; PbiRBC: P. berghei infected red blood cells;
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RAS: Radiation attenuated sporozoite; Tem: Cells with effector memory
phenotype.
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